Evolus (NASDAQ:EOLS) had its price objective lowered by JMP Securities from $35.00 to $30.00 in a research report sent to investors on Tuesday, The Fly reports. The brokerage currently has a market outperform rating on the stock. The analysts noted that the move was a valuation call.
A number of other research firms have also recently issued reports on EOLS. Zacks Investment Research cut Evolus from a buy rating to a hold rating in a research note on Friday, August 2nd. Cantor Fitzgerald reaffirmed a buy rating and set a $35.00 price target on shares of Evolus in a research note on Tuesday, April 30th. ValuEngine raised shares of Evolus from a hold rating to a buy rating in a research note on Thursday, July 18th. Mizuho set a $31.00 price target on shares of Evolus and gave the stock a buy rating in a research note on Monday, May 20th. Finally, Stifel Nicolaus set a $33.00 price target on shares of Evolus and gave the stock a buy rating in a research note on Wednesday, July 31st. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $26.78.
NASDAQ EOLS opened at $14.05 on Tuesday. The business has a 50 day simple moving average of $16.51 and a 200 day simple moving average of $20.48. Evolus has a 52-week low of $10.22 and a 52-week high of $30.25. The company has a debt-to-equity ratio of 1.87, a current ratio of 5.01 and a quick ratio of 14.52.
In other Evolus news, Director Simone Blank purchased 628,536 shares of the firm’s stock in a transaction dated Monday, May 20th. The stock was bought at an average cost of $19.25 per share, with a total value of $12,099,318.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director David N. Gill purchased 2,000 shares of the firm’s stock in a transaction dated Thursday, June 13th. The shares were acquired at an average cost of $13.65 per share, with a total value of $27,300.00. The disclosure for this purchase can be found here. Insiders have bought a total of 1,931,327 shares of company stock valued at $37,157,482 over the last ninety days. Company insiders own 3.90% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Patriot Financial Group Insurance Agency LLC boosted its holdings in shares of Evolus by 50.0% in the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 1,500 shares of the company’s stock valued at $34,000 after buying an additional 500 shares during the last quarter. Meeder Asset Management Inc. boosted its holdings in shares of Evolus by 48.9% in the 1st quarter. Meeder Asset Management Inc. now owns 1,732 shares of the company’s stock valued at $39,000 after buying an additional 569 shares during the last quarter. Pearl River Capital LLC boosted its holdings in shares of Evolus by 217.7% in the 1st quarter. Pearl River Capital LLC now owns 1,906 shares of the company’s stock valued at $44,000 after buying an additional 1,306 shares during the last quarter. BNP Paribas Arbitrage SA boosted its holdings in shares of Evolus by 8,877.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 1,975 shares of the company’s stock valued at $45,000 after buying an additional 1,953 shares during the last quarter. Finally, Edge Wealth Management LLC acquired a new stake in shares of Evolus in the 2nd quarter valued at approximately $29,000. 14.53% of the stock is owned by institutional investors.
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Article: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.